Site for Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck

Brief description of study

The purpose of the study is to determine whether docetaxel alone is as active as docetaxel and cetuximab combination and whether either taxane-based regimen is better than cisplatin monotherapy. Participants will receive one of the following treatments: standard treatment (radiation therapy and cisplatin), experimental treatment (radiation therapy and docetaxel), or experimental treatment (radiation therapy, docetaxel, and cetuximab). All of the drugs are commercially available, however the combination of drugs in this study is considered experimental.


Clinical Study Identifier: s16-01709
ClinicalTrials.gov Identifier: NCT01810913
Principal Investigator: Kenneth S Hu.
Other Investigators: Danny Perlaza, Tuyet-Phuong N Tran, Nora Russo, Elaine Shum, Adam S Jacobson, Christoph Maier, Joshua K Sabari, Marissa Rybstein, Moses M Tam, Caitlin Elizabeth Ryan, Zujun Li.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.